Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 32 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

6%

2 trials in Phase 3/4

Results Transparency

43%

3 of 7 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

30Total
Not Applicable (4)
Early P 1 (2)
P 1 (6)
P 2 (16)
P 3 (2)

Trial Status

Recruiting11
Completed7
Unknown4
Not Yet Recruiting4
Active Not Recruiting2
Withdrawn2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (32)

Showing 20 of 20 trials
NCT07554768Phase 2Not Yet Recruiting

Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC

NCT05172245Phase 1Recruiting

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

NCT07524452Phase 3RecruitingPrimary

Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT06129864Phase 3RecruitingPrimary

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT05269381Phase 1Recruiting

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

NCT07371234Phase 2RecruitingPrimary

Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07369882Not ApplicableRecruitingPrimary

Comparison of Efficacy Between De-escalated Surgery and Standard Surgery After Neoadjuvant Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT05245682Early Phase 1Active Not Recruiting

Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

NCT04454489Phase 2Completed

Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition

NCT07168785Early Phase 1Not Yet Recruiting

[18F]-AraG PET Imaging in LA HNSCC

NCT06959108Phase 2Not Yet RecruitingPrimary

Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

NCT03649048Not ApplicableRecruitingPrimary

Low-Dose Weekly vs High-Dose Cisplatin

NCT05527782Phase 2Active Not RecruitingPrimary

Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

NCT04733495Not ApplicableCompletedPrimary

Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment

NCT05743270Phase 2Withdrawn

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

NCT06470217Phase 2RecruitingPrimary

Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma

NCT05376553Phase 1Enrolling By InvitationPrimary

Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

NCT04870840Phase 1CompletedPrimary

Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer

NCT05724602Phase 2SuspendedPrimary

Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT06572514Phase 1RecruitingPrimary

De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC

Scroll to load more

Research Network

Activity Timeline